Drugs / BTX-9341
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06515470 | Jul 2024 → Sep 2027 expected | breast cancer | Biotheryx, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTX-9341 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06515470 ↗ |
| Route | Oral | “BTX-9341 capsule(s) administered orally once daily (QD) in 28-day cycles” NCT06515470 ↗ |